Making of an immuno therapeutic cum immuno prophylactic vaccine against leprosy endowed with multiple properties and useful applications

Reviewed briefly is the development of a unique vaccine against leprosy based on an autoclaved cultivable saprophytic mycobacteria, Mycobacterium indicus pranii (MIP, earlier coded as Mw). MiP is approved by the Drugs Controller General of India and by USFDA. It is transferred to industry and is ava...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical discovery 2017-08, Vol.2 (4), p.1-8
Main Author: Talwar, G.P.
Format: Article
Language:English
Subjects:
Antigens
Drugs
Immunology
Immunotherapy
Leprosy
Lymphocytes
Patients
Tuberculosis
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reviewed briefly is the development of a unique vaccine against leprosy based on an autoclaved cultivable saprophytic mycobacteria, Mycobacterium indicus pranii (MIP, earlier coded as Mw). MiP is approved by the Drugs Controller General of India and by USFDA. It is transferred to industry and is available to the public. Besides leprosy, MIP is in use as a potent adjuvant enhancing substantially antibody response to a potential Birth Control vaccine against hCG. MIP has both preventive and therapeutic actions against SP2/O myelomas in mice. It cures marvelously ugly warts on feet and in ano-genital regions by intralesional therapies. It has protective and therapeutic properties against tuberculosis.
ISSN:2476-129X
2476-129X
DOI:10.24262/jmd.2.4.17029